AU2112199A - Recombinant cell lines for drug screening - Google Patents

Recombinant cell lines for drug screening

Info

Publication number
AU2112199A
AU2112199A AU21121/99A AU2112199A AU2112199A AU 2112199 A AU2112199 A AU 2112199A AU 21121/99 A AU21121/99 A AU 21121/99A AU 2112199 A AU2112199 A AU 2112199A AU 2112199 A AU2112199 A AU 2112199A
Authority
AU
Australia
Prior art keywords
cell lines
recombinant cell
drug screening
screening
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21121/99A
Inventor
Samuel A. Clark
Christian Quaade
Anice E. Thigpen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagene Inc
Original Assignee
Betagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagene Inc filed Critical Betagene Inc
Publication of AU2112199A publication Critical patent/AU2112199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/74—Alginate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU21121/99A 1998-01-12 1999-01-11 Recombinant cell lines for drug screening Abandoned AU2112199A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US7119398P 1998-01-12 1998-01-12
US7255698P 1998-01-12 1998-01-12
US7120998P 1998-01-12 1998-01-12
US60071193 1998-01-12
US60072556 1998-01-12
US60071209 1998-01-12
US8784898P 1998-06-03 1998-06-03
US8782198P 1998-06-03 1998-06-03
US60087848 1998-06-03
US60087821 1998-06-03
PCT/US1999/000551 WO1999035495A2 (en) 1998-01-12 1999-01-11 Identification of substances that modify cellular secretory function

Publications (1)

Publication Number Publication Date
AU2112199A true AU2112199A (en) 1999-07-26

Family

ID=27535873

Family Applications (3)

Application Number Title Priority Date Filing Date
AU24551/99A Abandoned AU2455199A (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines
AU21131/99A Abandoned AU2113199A (en) 1998-01-12 1999-01-11 Media for neuroendocrine cells
AU21121/99A Abandoned AU2112199A (en) 1998-01-12 1999-01-11 Recombinant cell lines for drug screening

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU24551/99A Abandoned AU2455199A (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines
AU21131/99A Abandoned AU2113199A (en) 1998-01-12 1999-01-11 Media for neuroendocrine cells

Country Status (4)

Country Link
EP (2) EP1047938A2 (en)
AU (3) AU2455199A (en)
CA (2) CA2318376A1 (en)
WO (3) WO1999035495A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2281764C2 (en) * 2000-03-17 2006-08-20 Адзиномото Ко., Инк. Medicinal agents for treatment of complications associated with diabetes mellitus and neuropathy and their using
US7501231B2 (en) 2001-03-23 2009-03-10 University Of Ottawa Methods and compositions for cryopreservation of dissociated primary animal cells
US7166463B2 (en) 2001-11-16 2007-01-23 The Regents Of The University Of Colorado Nucleic acids encoding modified olfactory cyclic nucleotide gated ion channels
ES2557475T3 (en) 2005-06-17 2016-01-26 Vital Health Sciences Pty Ltd. A carrier comprising one or more di- and / or monophosphate derivatives of electron transfer agents
EP1767545B1 (en) 2005-09-22 2009-11-11 Biocompatibles UK Limited GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
RU2486236C2 (en) 2006-01-04 2013-06-27 Бакстер Интернэшнл Инк. Method of protein expression
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
JP5401310B2 (en) 2006-07-13 2014-01-29 ワイス・エルエルシー Glycoprotein production
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
CN101679944A (en) 2007-05-01 2010-03-24 维特罗莱夫瑞典有限公司 The substratum that contains elevated concentrations of lipoic acid that is used for developmental cells
AU2008297930A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of octreotide as a therapeutic agent
EP2163243A1 (en) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
RU2017138926A (en) 2009-08-11 2019-02-11 Дженентек, Инк. PRODUCTION OF PROTEINS IN CULTURAL MEDIA WITHOUT GLUTAMINE
AU2011213557B2 (en) 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
MX2012009068A (en) * 2010-02-05 2012-09-07 Phosphagenics Ltd Carrier composition.
MX2012011355A (en) 2010-03-30 2012-11-30 Phosphagenics Ltd Transdermal delivery patch.
US9540607B2 (en) 2011-02-22 2017-01-10 Cytonet, Llc Fill system for providing uniform concentrations and volumes and methods thereof
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US8945876B2 (en) 2011-11-23 2015-02-03 University Of Hawaii Auto-processing domains for polypeptide expression
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
WO2015066631A2 (en) * 2013-11-01 2015-05-07 University Of Notre Dame Du Lac Cell culture medium and bioprocess optimization
ES2716674T3 (en) * 2013-11-22 2019-06-14 Centre Nat Rech Scient Frozen cell ready for testing and method to minimize variability in the performance of the same
US10918110B2 (en) 2015-07-08 2021-02-16 Corning Incorporated Antimicrobial phase-separating glass and glass ceramic articles and laminates
TW202340452A (en) * 2015-08-04 2023-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
CA3007587C (en) 2015-12-09 2023-12-05 Phosphagenics Limited Pharmaceutical formulation
WO2018112512A1 (en) 2016-12-21 2018-06-28 Phosphagenics Limited Process
KR102569522B1 (en) * 2017-11-24 2023-08-24 주식회사 차바이오랩 Composition for cryopreservation of cell and method for cryopreservation of cell using the same
US20230091910A1 (en) * 2019-04-02 2023-03-23 Centagen, Inc. Engineered System of Stem Cell Rejuvenation to Treat Aging and Disease
CN114868736B (en) * 2022-03-08 2022-12-09 四川中科奥格生物科技有限公司 Islet cell stabilizing solution and preparation method and application thereof
CN114561337B (en) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 Monoclonal enhancement culture medium and method for improving clone formation rate of HepG2 cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180662A (en) * 1988-01-05 1993-01-19 The United States Of America As Represented By The Department Of Health And Human Services Cytotoxic T lymphocyte activation assay
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
CA2051092C (en) * 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
DE550760T1 (en) * 1991-07-18 1994-02-03 Fuji Yakuhin Kogyo Kk SERUM-FREE TISSUE CULTURE MEDIA CONTAINING A TISSUE INHIBITOR OF METAL PROTEINASE AND METHODS OF CELL GROWTH.
GB9125052D0 (en) * 1991-11-26 1992-01-22 Isis Innovation Culture of bone cells
FR2726005B1 (en) * 1994-10-10 1997-01-03 Adim IMMORTALIZED LINES OF CEREBRAL ENDOTHELIAL CELLS AND THEIR APPLICATIONS FOR THE TREATMENT OF DIFFERENT NEUROLOGICAL OR PSYCHIATRIC PRIMARY AND SECONDARY DISORDERS OR DISEASES
CA2246431A1 (en) * 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines

Also Published As

Publication number Publication date
EP1047938A2 (en) 2000-11-02
WO1999035495A2 (en) 1999-07-15
WO1999035255A2 (en) 1999-07-15
WO1999035255A3 (en) 1999-10-28
EP1045898A2 (en) 2000-10-25
AU2113199A (en) 1999-07-26
WO1999035242A1 (en) 1999-07-15
AU2455199A (en) 1999-07-26
CA2318376A1 (en) 1999-07-15
CA2318379A1 (en) 1999-07-15
WO1999035255A9 (en) 2001-05-31
WO1999035242A9 (en) 1999-09-30
WO1999035495A3 (en) 1999-11-25
WO1999035255A8 (en) 1999-09-10

Similar Documents

Publication Publication Date Title
AU2112199A (en) Recombinant cell lines for drug screening
AU2073801A (en) A system for cell-based screening
AU1225000A (en) Combined pharmaceutical estrogen-androgen-progestin
AU4488200A (en) Modified protein matrices
AU4509699A (en) Loading arrangement
AU1685600A (en) Polypeptides
AU2051301A (en) Cervical screening system
AU2925600A (en) Genetic screening
AU1656401A (en) A system for cell-based screening
AU6622800A (en) A system for cell-based screening
AU1409100A (en) Drugs
AU5269900A (en) A system for cell-based screening
AU7132898A (en) Edg-1-like receptor
AU6155398A (en) Methods for screening for antibiotics
AU4077099A (en) Cell signaling proteins
AU7131900A (en) A system for cell-based screening
AU1618500A (en) Human cell surface receptor proteins
AU4930399A (en) Novel Polypeptide
AU5566799A (en) Electrodes
AU5706000A (en) Useful polypeptide
AUPP332898A0 (en) Pharmaceutical composition
AU7432998A (en) Arid-polymer construction material
AU8243798A (en) Agm-derived stroma cells
AUPQ314799A0 (en) Bone cell factor
AU4411699A (en) Interferon receptor hkaef92

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase